| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 12/18/2003 | US20030232871 Crystalline parecoxib sodium |
| 12/18/2003 | US20030232861 Reacting magnesium with lower alcohol to produce magnesium alkoxide, adding omeprazole, then flash-evaporating solvent; for treatment of gastrointestinal inflammatory diseases |
| 12/18/2003 | US20030232858 Use of hydroxyeicosatetraenoic acid compounds to treat dry mouth |
| 12/18/2003 | US20030232857 Side effects reduction; for treating nervous system disorders (attention deficit/hyperactivity, and cognitive decline associated with acquired immunodeficiency syndrome) |
| 12/18/2003 | US20030232851 Viral treatment |
| 12/18/2003 | US20030232813 Novel amino substituted pyrimidinone derivatives |
| 12/18/2003 | US20030232796 Nanoparticulate polycosanol formulations & novel polycosanol combinations |
| 12/18/2003 | US20030232748 Insulin aspart and insulin detemir in a specific ratio; antidiabetic agent |
| 12/18/2003 | US20030232177 Jelly pen holder |
| 12/18/2003 | US20030232118 Beverages containing plant sterols |
| 12/18/2003 | US20030232101 Topical formulations of resorcinols and cannibinoids and methods of use |
| 12/18/2003 | US20030232099 Powder and an extract of lotus root joints; improves insulin resistance, for diabetes, obesity, hyperlipidemia, hypertension, thrombosis, Alzheimer's disease and senility |
| 12/18/2003 | US20030232097 Oily wax matrix suspension formulation comprising ibuprofen free acid and potassium salt of ibuprofen |
| 12/18/2003 | US20030232095 Use enhancing bioavailability of oil-soluble, oil non-soluble or water-soluble nutraceuticals, foods, supplements, plant extracts, drugs, peptides, proteins or carbohydrates |
| 12/18/2003 | US20030232092 Liquid antacid compositions |
| 12/18/2003 | US20030232090 Anhydrous antifungal gel comprising polyhydric alcohol(s), a gelling agent and an antifungal azole such as econazole; treating oral and vaginal fungal and bacterial infections |
| 12/18/2003 | US20030232089 Gum increases the retention time of the active agent in the eye; e.g. konjac, scleroglucan, hydroxypropyl guar, propylene glycol alginate, sodium alginate, a trademarked carbomer, pectin, agarose and hydroxypropylmethyl cellulose |
| 12/18/2003 | US20030232088 Copolymer or interpolymer complex of a polycarboxylic acid bioadhesive polymer and a biodegradable polymer; for example a graft copolymer of (meth)acrylic acid and lactic acid; drug delivery applicatons; tampons |
| 12/18/2003 | US20030232085 Polymeric delivery agents and delivery agent compounds |
| 12/18/2003 | US20030232083 Modified release dosage form |
| 12/18/2003 | US20030232082 Modified release dosage forms |
| 12/18/2003 | US20030232081 Pharmaceutical composition for controlled drug delivery system |
| 12/18/2003 | US20030232080 For enhancing dissolution and absorption of active ingredients |
| 12/18/2003 | US20030232079 DPC 333 formulation having unique biopharmaceutical characteristics |
| 12/18/2003 | US20030232078 Formulation & dosage form for the controlled delivery of therapeutic agents |
| 12/18/2003 | US20030232077 Rapidly disintegrating tablet |
| 12/18/2003 | US20030232076 For encapsulating medication or other consumables; texture and chewability, storage qualities |
| 12/18/2003 | US20030232075 For therapy of clotting disorder |
| 12/18/2003 | US20030232073 Enhanced drug delivery in transdermal systems |
| 12/18/2003 | US20030232072 Pharmaceutical composition and method for treating hypogonadism |
| 12/18/2003 | US20030232070 Antifungal nail lacquer and method using same |
| 12/18/2003 | US20030232069 For temporarily lifting, supporting or smoothing the skin |
| 12/18/2003 | US20030232065 Exposing an upper vertebra and a lower vertebra; identifying site for fusion between upper and lower vertebra; exposing bone surface on each of upper and lower vertebra at site for fusion; administering HMG-CoA reductase inhibitor to the site |
| 12/18/2003 | US20030232020 Used for delivery using a dry powder inhaler (DPI) or similar delivery device |
| 12/18/2003 | US20030232019 Inhalable formulations for sustained release |
| 12/18/2003 | US20030232018 Stabilized formulations of adenovirus |
| 12/18/2003 | US20030230590 Automatic medicament dispenser system |
| 12/18/2003 | US20030229946 Polymeric surfactant compositions and methods of manufacture and use |
| 12/18/2003 | CA2489076A1 Cryopreservation of haptenized tumor cells |
| 12/18/2003 | CA2488691A1 Extended release formulation of divalproex sodium |
| 12/18/2003 | CA2488617A1 Nanoparticulate sterol formulations and sterol combinations |
| 12/18/2003 | CA2488613A1 Novel formate salt of o-desmethyl-venlafaxine |
| 12/18/2003 | CA2488558A1 Prevention and reduction of blood loss |
| 12/18/2003 | CA2488498A1 Nanoparticulate polycosanol formulations and novel polycosanol combinations |
| 12/18/2003 | CA2488403A1 Pharmaceutical formulation |
| 12/18/2003 | CA2488385A1 Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s) |
| 12/18/2003 | CA2488360A1 Covalent conjugates between artemisinin-related endoperoxides and iron-carrying proteins and methods of use |
| 12/18/2003 | CA2488354A1 Solubilisation of drugs in hfa propellant by means of emulsions |
| 12/18/2003 | CA2488347A1 Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer |
| 12/18/2003 | CA2488108A1 Liquid formulation of decitabine and use of the same |
| 12/18/2003 | CA2488059A1 Non-polymeric hematopoietic cell clots for delivery of active agents |
| 12/18/2003 | CA2487961A1 Method and composition for improving sensory characteristics of semisolid predominantly anhydrous |
| 12/18/2003 | CA2487889A1 Stabilised pharmaceutical compositions on the basis of polyoxyethylated castor oil and method for manufacturing the same |
| 12/18/2003 | CA2487413A1 Methods of treating angiogenesis, tumor growth, and metastasis |
| 12/18/2003 | CA2486270A1 Vegfr modulating agents and methods for liver growth and liver protection |
| 12/18/2003 | CA2484514A1 Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions |
| 12/17/2003 | EP1371692A1 Auto inversible inverse Microlatex, process for its preparation and its utilization |
| 12/17/2003 | EP1371591A2 Method and device for inserting a plurality of individual sheetlike dosage forms in a dispenser by forming a multilayer pile |
| 12/17/2003 | EP1371369A1 Compositions comprising remifentanil |
| 12/17/2003 | EP1371365A1 Emulsion/aggregation processes as methods for forming polymeric microspheres characterized by narrow particle size distribution for biomedical human and veterinary administration |
| 12/17/2003 | EP1371364A1 Proces for the preparation of a controlled release system |
| 12/17/2003 | EP1371363A1 Use of an enzymatically converted starch derivative as an encapsulating agent |
| 12/17/2003 | EP1371362A1 Composition for treatment of inflammatory disorders |
| 12/17/2003 | EP1371361A1 Novel suppository form comprising an acid-labile active compound |
| 12/17/2003 | EP1371360A1 Device for containing a pharmaceutical composition |
| 12/17/2003 | EP1370530A1 Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical |
| 12/17/2003 | EP1370352A1 Method for encapsulating fine solid particles in the form of microcapsules |
| 12/17/2003 | EP1370312A1 Method and apparatus to control drug therapy dosages in an implantable pump |
| 12/17/2003 | EP1370302A1 Dry powder compositions comprising labelled particles for inhalation |
| 12/17/2003 | EP1370293A2 Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists |
| 12/17/2003 | EP1370285A2 A vaccine composition and method of using the same |
| 12/17/2003 | EP1370280A2 Stabilized interleukin 2 |
| 12/17/2003 | EP1370274A1 Compositions comprising matrine and dictamnine for treating or preventing cancer and other diseases |
| 12/17/2003 | EP1370271A2 A process for the manufacture of a herbal composition comprising a matrine |
| 12/17/2003 | EP1370268A2 Methods for treating stress disorders using glucocorticoid receptor-specific antagonists |
| 12/17/2003 | EP1370259A1 Use of melatonin in the manufacture of a medicament for treating attention deficit hyperactive disorder |
| 12/17/2003 | EP1370257A1 Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids |
| 12/17/2003 | EP1370251A1 Topical patch preparation containing a delayed-type hypersensitivity inducer and methods for using the same |
| 12/17/2003 | EP1370249A1 Novel dendriticpolymers and their biomedical uses |
| 12/17/2003 | EP1370247A2 Taste masked pharmaceutical compositions |
| 12/17/2003 | EP1370246A2 Modulation of release from dry powder formulations |
| 12/17/2003 | EP1370245A1 Method to prepare microparticles metoprolol that contain |
| 12/17/2003 | EP1370244A1 Novel tablets and capsules and a process for its preparation |
| 12/17/2003 | EP1370243A1 Method to obtain microparticles containing a h+, k+ -atp-ase inhibitor |
| 12/17/2003 | EP1370242A1 Method to obtain microparticles containing a h+, k+ -atp-ase inhibitor |
| 12/17/2003 | EP1370241A1 Multi-lamellar emulsion(mle) for stabilizing dermatologically useful ingredients and external base preparations for general skin diseases utilizing the same |
| 12/17/2003 | EP1370239A1 New composition |
| 12/17/2003 | EP1370238A1 Liquid formulations for electrohydrodynamic spraying containing polymer and suspended particles |
| 12/17/2003 | EP1370228A2 Systems for delivering a cosmetic and/or therapeutic active to oral surfaces |
| 12/17/2003 | EP1370212A1 System and method for intranasal administration of lorazepam |
| 12/17/2003 | EP1370206A1 Devices for local and systemic delivery of active substances and methods of manufacturing thereof |
| 12/17/2003 | EP1370152A2 Polybutene containing chewing gum and confection |
| 12/17/2003 | EP1370150A1 One-step process for preparing chewing gum |
| 12/17/2003 | EP1370148A1 Anticholesterolemic edible oil |
| 12/17/2003 | EP1294363B1 Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
| 12/17/2003 | EP1272470B1 Amorphous torasemide modification |
| 12/17/2003 | EP1196148B1 Process for microencapsulation of water soluble substances |
| 12/17/2003 | EP1171471B1 Enhanced gel strength methylcellulose |
| 12/17/2003 | EP1126891B1 Method of depositing a dry powder and dispensing device |
| 12/17/2003 | EP1112065B1 Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose deivative |